CMS chief declines to provide details on Trump healthcare plan

The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation...

R&D leaders worry pharma reputation risks losing talent

PHILADELPHIA — It's not artificial intelligence or creative corporate structures that some of the biopharma industry's leaders see as the best way to boost R&D...

PhRMA’s DTC defense rolls out on airwaves and online

The move by PhRMA and its members to address calls for more transparency on drugs prices came to a head in October, when the trade...

AstraZeneca inks ambitious $6.9B deal for Daiichi cancer therapy

Long known for its prowess in cardiovascular and respiratory diseases, AstraZeneca has joined its pharmaceutical peers in making a bigger play in oncology. While the...
A filing this year for filgotinib could set up a potential market launch in 2020, which would be one to two years earlier than...
In an era of criticism and scrutiny for biopharma companies, executives gathered at the 2019 BIO meeting have debated how the industry can push...
Neither Pfizer or Novartis are among the handful of companies at the leading edge of NASH drug development, which has yet to advance a...

Follow RXMonthly

News

Sangamo backs up early success for hemophilia gene therapy

In gene therapy, where dramatic results in deadly diseases can hasten clinical testing, studies tend to be smaller, with greater significance put on each...

Nonprofit under pressure to make new TB drug affordable

Authorities warn that antibiotic-resistant infections rank high, if not at the top, of public and global health concerns. TB offers a prime...

Gilead to build manufacturing site in Maryland to boost...

The new facility should help the big biotech meet some of the unique challenges of manufacturing CAR-T therapies. The process is complex and time...

Catalent to buy Paragon for $1.2B as gene therapy...

Biologics have been a business boon to contract manufacturers, Catalent included. Large-molecule drugs are such a focus, in fact, that last year Catalent split its...

Latest articles

CMS chief declines to provide details on Trump healthcare plan

The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...

Roche cancer drug the 3rd approved for pan-tumor use

Aimed at the molecular catalysts of tumor growth, targeted therapies are treatment mainstays across a wide range of cancer types. 

Novo faces shareholder suit over insulin sales disclosures

Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...

Celgene wins approval for drug key to Bristol buyout

Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene's product pipeline. 

Subscribe to our newsletter